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Edited by Horst FeldmannAbstract Visceral fat accumulation has been shown to play cru-
cial roles in the development of cardiovascular disease as well as
the development of obesity-related disorders such as diabetes
mellitus, hyperlipidemia and hypertension and the so-called met-
abolic syndrome. Given these clinical ﬁndings, adipocytes func-
tions have been intensively investigated in the past 10 years,
and have been revealed to act as endocrine cells that have been
termed adipocytokines, which secrete various bioactive sub-
stances. Among adipocytokines, tumor necrosis factor-a, plas-
minogen activator inhibitor type 1 and heparin binding
epidermal growth factor-like growth factor are produced in adi-
pocytes as well as other organs, and may contribute to the devel-
opment of vascular diseases. Visfatin has been identiﬁed as a
visceral-fat-speciﬁc protein that might be involved in the develop-
ment of obesity-related diseases, such as diabetes mellitus and
cardiovascular disease. On the contrary to these adipocytokines,
adiponectin, an adipose-tissue-speciﬁc, collagen-like protein, has
been noted as an important antiatherogenic and antidiabetic pro-
tein, or as an anti-inﬂammatory protein. The functions of adipo-
cytokine secretion might be regulated dynamically by nutritional
state. Visceral fat accumulation causes dysregulation of adipo-
cyte functions, including oversecretion of tumor necrosis fac-
tor-a, plasminogen activator inhibitor type 1 and heparin
binding epidermal growth factor-like growth and hyposecretion
of adiponectin, which results in the development of a variety of
metabolic and circulatory diseases. In this review, the importance
of adipocytokines, especially focusing on adiponectin is discussed
with respect to cardiovascular diseases.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cardiovascular disease has been recognized to be a biggest
target for worldwide preventive medicine since this disease
comprises about 30% of the cause of death in all over the world
according to World Health Report from World Health Orga-
nization. Hypercholesterolemia has been considered to be the
strongest risk factor for atherosclerosis and cholesterol lower-
ing treatment has been located in the center of preventive med-
icine for cardiovascular disease. However, it is well-known that
substantial proportion of the subjects with cardiovascular dis-
ease do not necessarily show hypercholesterolemia and other*Fax: +81 6 6444 3975.
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doi:10.1016/j.febslet.2006.04.028risk sate than hypercholesterolemia should be considered. In
the end of 1980s, the concept of multiple risk factor clustering
syndrome has been proposed as a highly atherogenic state
independent from hypercholesterolemia [1,2]. A variety of
common disorders, such as hyperglycemia, hyperlipidemia
and hypertension, are seen in individuals with this syndrome,
and cardiovascular disease is very prevalent and this syndrome
has been called to be metabolic syndrome. The disorders such
as diabetes, dyslipidemia and hypertension are not clustered
coincidently, and there is thought to be a key to the simulta-
neous development within certain individuals along with the
associated development of cardiovascular disease.
Insulin resistance has been long considered to have a central
role in the development of a range of metabolic disorders [3].
However these disorders that contribute to the metabolic syn-
drome, except for hyperglycemia, cannot be interpreted by
insulin resistance. In a consensus on the deﬁnition of metabolic
syndrome from the International Diabetes Federation, the cru-
cial, direct roles of intra-abdominal visceral fat accumulation
in the development of multiple risks and cardiovascular disease
have been recognized. My group and others have proposed the
concept of a visceral fat syndrome because of our computed
tomography, CT ﬁndings in the analysis of intra-abdominal
visceral fat [4]. An important question is, then, why visceral
fat accumulation causes common disorders; more importantly,
why is this syndrome so atherogenic? In order to answer these
questions, we have investigated the functions of adipose-tissue,
which has been traditionally regarded as a tissue passively stor-
ing excess energy in the form of triglycerides. In this review, I
would like to show the importance of visceral adiposity in the
development of metabolic syndrome and also discuss crucial
roles of adipocytokines in the mechanism of a variety of dis-
eases including atherosclerosis.2. Visceral fat accumulation and multiple risk factors
A number of clinical studies have demonstrated the impor-
tance of fat distribution and especially the contribution of vis-
ceral fat accumulation to the development of metabolic
disorders, including glucose intolerance and hyperlipidemia.
Our studies have demonstrated that visceral fat area deter-
mined by CT, correlates signiﬁcantly with glucose area after
oral glucose tolerance test, and with cholesterol and triglycer-
ide levels [5,6]. Visceral fat accumulation is associated not only
with quantitative changes in serum lipids and lipoproteins and
but also with qualitative changes in lipoproteins, such as small
dense LDL. These changes could be related to the high-triglyc-
eride, low HDL dyslipidemic state. Insulin resistance orblished by Elsevier B.V. All rights reserved.
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one of key abnormalities related to metabolic disorders. Stud-
ies on muscle glucose uptake reported by Evans et al. [7] and
the steady-state plasma glucose method by our group, [8]
clearly show that visceral fat obesity has greater insulin resis-
tance than subcutaneous fat obesity.
In addition to these metabolic disorders, we have dem-
onstrated that in premenopausal women visceral fat accu-
mulation correlates closely with systolic blood pressure [9].
In hypertensive people, we reported a close correlation be-
tween the extent of visceral fat reduction, not subcutaneous
fat reduction, and a lowering of blood pressure after weight
reduction.
Visceral fat accumulation relates to the development of car-
diovascular risks mentioned above and might relate directly to
the development of cardiovascular disease. Epidemiologic
studies have suggested that waist-to-hip ratio is a signiﬁcant
predictor for coronary artery disease independent of BMI
[10]. Furthermore, several studies, including ours, have shown
that visceral adiposity determined by CT scanning is related to
coronary artery disease even in mildly obese individuals [11].
Visceral fat accumulation is also related to the development
of cardiac dysfunction and sleep apnea syndrome [12,13].
From these evidences, we can conclude that visceral fat accu-
mulation is a major risk of cardiovascular disease as well as
metabolic diseases (see Fig. 1).3. Cardiovascular risks and vascular changes related to visceral
fat accumulation
3.1. The concept of adipocytokines
To elucidate the molecular mechanism of visceral fat-related
diseases, particularly those in the metabolic syndrome, we have
investigated the biological characteristics of visceral adiposeFig. 1. The mechanism of prevention of atherosclerosis and plaque
rapture by adiponectin. Adipocytes abundantly secrete adiponectin
into plasma which ﬂow with blood stream inside of vascular walls.
Adiponectin gets into injured vascular walls by binding subendothelial
collagens and may inhibit monocyte adhesion to endothelial cells
through inhibition of adhesion molecule expression, inhibit smooth
muscle cell proliferation and inhibit cholesterol accumulation in
macrophages by inhibiting scavenger receptor expression. In addition
to these functions, adiponectin may also protect plaque rapture by
inducing tissue inhibitor of metalloproteinase [39–43].tissue and subcutaneous adipose tissue by analysis of the
gene-expression proﬁle compared with that of other mesenchy-
mal cells. We systematically analyzed active genes by con-
structing a 3 0-directed complementary DNA library in which
the messenger RNA population was faithfully reﬂected. We
found an unexpectedly high frequency of the genes encoding
secretary proteins in adipose tissue, most of which are impor-
tant bioactive substances. Of the gene group classiﬁed by func-
tions and subcellular localization, approximately 20% of all
genes in subcutaneous adipose tissue encode secretory pro-
teins. This frequency rises to about 30% in visceral adipose tis-
sue. We classiﬁed these adipose-tissue-derived bioactive
substances as adipocytokines.
The importance of adipocytokines is highlighted by the
fact that adipose tissue is one of the largest organs in the
body. The total amount of an adipocytokine secreted from
whole adipose tissue might, therefore, aﬀect the whole body
even if the amount secreted from each adipocyte is small.
Another notable feature is the fact that each adipocyte is
connected to the vascular network. Adipocytokines released
from adipocytes ﬂow easily, therefore, into the systemic cir-
culation [14].3.2. Adipocytokines and diseases
Leptin, a bioactive substance that controls food intake and
energy expenditure, and tumor necrosis factor-a are secreted
from adipose tissue and can induce insulin resistance [15]. We
found that the genes encoding plasminogen activator inhibi-
tor type 1 (PAI-1) and heparin binding epidermal growth fac-
tor-like growth factor are highly expressed in adipose tissue
[16,17]. PAI-1 messenger RNA concentrations increased up
to 10-fold in visceral adipose tissue during development of
fat accumulation in ventromedial hypothalamic-lesioned rats,
which is an experimental animal model of obesity. In subcu-
taneous adipose tissue, concentrations remained unchanged.
In addition to the animal model, we demonstrated that plas-
ma levels of PAI-1 were signiﬁcantly correlated with visceral
adiposity, assessed by CT scanning, in humans. Circulating
PAI-1 is deemed as a strong risk factor for thrombotic dis-
eases, including acute myocardial infarction, in metabolic
syndrome [18]. Heparin binding epidermal growth factor-like
growth factor, a potent factor for smooth-muscle-cell prolif-
eration, secreted from accumulated adipose tissue could also
have some signiﬁcance for vascular remodeling in obesity.
During our search for visceral-fat-speciﬁc adipocytokines by
a diﬀerential display method, we detected a unique molecule
encoded by a gene that was exclusively expressed in the vis-
ceral fat samples. This complementary DNA fragment corre-
sponds to the 5 0-untranslated region of the gene encoding
pre-B-cell colony-enhancing factor. We named the protein
visfatin and established an assay system. Plasma visfatin lev-
els correlated strongly with the amount of visceral fat on CT
[19]. Physiologic and pathologic signiﬁcance are not fully
known. We have demonstrated that visfatin exerts insulin-mi-
metic eﬀects in culture cells and has a potent activity of adi-
pogenesis as much as that of insulin. Visfatin exclusively
secreted from visceral adipose tissue might have, therefore,
an important role in rapid accumulation of visceral fat via
an autocrine or paracrine route. Further studies are neces-
sary for the roles of visfatin in the development of metabolic
syndrome.
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When we started the comprehensive genetic analysis of hu-
man adipose tissue, 40% of the expressed genes were previously
unknown genes. The gene expressed most abundantly in adi-
pose tissue, which we named adipose most abundant gene tran-
script-1, apM-1, was a novel gene [20]. The molecule encoded
by apM-1 possesses a signal peptide, collagen-like motif and
globular domain, and has notable homology with collagen X,
VIII and complement factor C1q. We termed the collagen-like
protein adiponectin. The mouse homolog of adiponectin has
been cloned as ACRP30 [21]. We established the method for
the measurement of plasma adiponectin levels using enzyme-
linked immunosorbent assay. The average levels of adiponectin
in human plasma are extremely high-up to 5–10 lg/ml [22].
Plasma concentrations are negatively correlated with BMI,
whereas leptin increases with BMI. The negative correlation
of adiponectin levels and visceral adiposity is stronger than be-
tween adiponectin levels and subcutaneous adiposity.
The mechanism by which plasma levels are reduced in indi-
viduals with visceral fat accumulation is not yet clariﬁed. Co-
culture with visceral fat inhibits adiponectin secretion from
subcutaneous adipocytes. This ﬁnding suggests that some
inhibiting factors for adiponectin synthesis or secretion are
secreted from visceral adipose tissue [23]. Tumor necrosis
factor-a was reported to be a strong inhibitor of adiponectin
promoter activity [24]. The negative correlation between
visceral adiposity and adiponectin levels might be explained
by the increased secretion of this cytokine from accumulated
visceral fat as at least one mechanism.
Plasma adiponectin concentrations are lower in people who
have type 2 diabetes mellitus than in BMI-matched controls
[25]. The plasma concentrations have been shown to correlate
strongly with insulin sensitivity, which suggests that low plasma
concentrations are related to insulin resistance [26]. In a study
of Pima Indians, individuals with high levels of adiponectin
were less likely than those with low concentrations to develop
type 2 diabetes. High adiponectin concentration was, there-
fore, a notable protective factor against development of type
2 diabetes [27].
Studies on adiponectin knockout mice support observations
in humans. The KO mice showed no speciﬁc phenotype when
they were fed a normal diet but a high-sucrose and high-fat
diet induced a marked elevation of plasma glucose and insulin
levels. Notable insulin resistance, estimated by insulin toler-
ance test during the high-sucrose with high-fat diet, also devel-
oped in the knockout mice. The supplementation of
adiponectin by adenovirus transfection clearly improved this
insulin resistance [28]. Although I will not mention the details
of molecular mechanism, adiponectin has been shown to exert
its actions on muscle fatty acid oxidation and insulin sensitiv-
ity by activation of AMP-activated protein kinase [29]. Plasma
levels of adiponectin are also decreased in hypertensive hu-
mans, irrespective of the presence of insulin resistance [30].
Endothelium-dependent vasoreactivity is impaired in people
with hypoadiponectinemia, which might be at least one mech-
anism of hypertension in visceral obesity [31].
Most importantly, plasma concentrations of adiponectin are
lower in people with coronary heart disease than in controls
even when BMI and age are matched [32]. Kaplan–Meier anal-
ysis in Italian individuals with renal insuﬃciency demonstrated
that those with high adiponectin concentrations were free from
cardiovascular death for longer than other groups [33]. A case–control study performed in Japan demonstrated that the group
with hypoadiponectinemia with the plasma levels less than
4 lg/ml has been shown to have increased risk of CAD and
multiple metabolic risk factors, which indicates that hypoa-
diponectinemia is a key factor in the metabolic syndrome
[34]. A prospective study by Piscon et al. [35] conﬁrmed that
high adiponectin concentrations are associated with reduced
risk of acute myocardial infarction in men. In addition to hyp-
oadiponectinemia accompanied with visceral fat accumulation,
genetic hypoadiponectinemia caused by a missense mutation
has been reported, which also exhibit the clinical phenotype
of metabolic syndrome [36].
These clinical evidences show that hypoadiponectinemia is a
strong risk factor for cardiovascular disease.4. Cell biological functions of adiponectin
Antiatherogenicity of adiponectin is also demonstrated in
animal experiments. Adiponectin knockout mice developed
more-severe intimal thickening by endothelial injury than did
wild-type mice [37]. In addition, overexpression of human
adiponectin by adenovirus transfection attenuated plaque for-
mation in apolipoprotein E-KO mice [38].
A large amount of adiponectin ﬂows with the blood stream
and, therefore, comes into contact with the vascular walls all
over the body. The ways in which adiponectin interacts with
vascular cells would be important to know. Immunohisto-
chemical examination with antibodies to adiponectin showed
no adiponectin protein in the untreated normal vascular walls
in rabbits. Markedly positive immunohistochemical staining
was detected, however, in balloon-injured vascular walls. Since
adiponectin has the ability to bind subendothelial collagens
such as collagen V, VIII and X, endothelial injury may induce
the adiponectin from entering into the subendothelial space
through binding to these collagens [39].
Cell biological studies have demonstrated that adiponectin
has multiple, potent antiatherogenic functions. When the
endothelial barrier is injured by attacking factors such as oxi-
dized LDL, chemical substances and mechanical stress, adipo-
nectin accumulates in the subendothelial space of vascular
walls by binding to subendothelial collagen, at which point
antiatherogenic properties of adiponectin become apparent
[39]. The protein suppresses monocyte attachment to vascular
endothelial cells by inhibiting the expression of adhesion mol-
ecules, such as vascular cell adhesion molecule 1, intracellular-
adhesion molecule 1 and E-selectin via the inhibition of NF-jB
activation [40]. Adiponectin also attenuates growth-factor-in-
duced proliferation of vascular smooth-muscle cells by the
inhibition of mitogen-activated protein kinase [41]. Adiponec-
tin suppresses foam-cell formation by the inhibition of expres-
sion of scavenger receptor class A [42].
Acute coronary syndromes are considered to determine
the prognosis of cardiovascular disease in which vulnerability
of plaque is the important determinant of plaque rupture. In
this process, matrix metalloproteinase secreted from macro-
phages is thought to play an important part in plaque vulnera-
bility. Tissue inhibitor of metalloproteinase is thought to
act as a protector of plaque rapture by inhibition of matrix
metalloproteinase. Adiponectin increases the expression of
messenger RNA and protein production of tissue inhibitor of
metalloproteinase in macrophages via the induction of
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protects plaque rapture by the inhibition of matrix metallopro-
teinase function, through the induction of interleukin-10-
dependent production of tissue inhibitor of metalloproteinase
[43]. Final prognosis of cardiovascular disease depends on car-
diac function and visceral fat accumulation was reported to be
related to cardiac dysfunction.
Shibata et al. have demonstrated that adiponectin-deﬁcient
mice shows enhanced concentric hypertrophy and increased
mortality under pressure overload. These phenomena were
associated with increased extracellular signal-regulated kinase
and diminished AMP-activated protein kinase signaling in
the myocardium. Adenovirus-mediated supplementation of
adiponectin attenuated cardiac hypertrophy in response to
pressure overload [44].5. Establishment of a disease entity-hypoadiponectinemia
As shown above, it is no doubt that adiponectin is the most
important adipocytokine which prevent cardiovascular disease
as well as metabolic diseases including type 2 diabetes. In other
words, hypoadiponectinemia has been demonstrated to be re-
lated to a variety of major diseases such as cardiovascular dis-
ease and metabolic disease, namely metabolic syndrome which
may threaten life [45]. Therefore, I would like to propose a dis-
ease entity named hypoadiponectinemia.
Hypoadiponectinemia may be classiﬁed into two types; one
is primary hypoadiponectinemia which may be caused by ge-
netic disorders [36] and the other is secondary hypoadiponec-
tinemia which is caused by visceral fat accumulation. The
later is corresponding to metabolic syndrome and much more
frequent than primary one. Then I expect the development of
therapeutic strategy which can elevate plasma levels of adipo-
nectin, as statin was developed for hypercholesterolemia.6. Therapeutic perspectives of adiponectin
The clinical and experimental evidence of adiponectin’s anti-
atherogenicity might lead to the development of new therapeu-
tic strategies for cardiovascular disease, diabetes mellitus and
even the metabolic syndrome [45]. Given the high plasma levels
of adiponectin in humans, direct administration of adiponectin
protein to individuals with chronic disease might not be a good
idea because of diﬃculties in maintaining high plasma levels. In
addition, adiponectin acts potently in the high-molecular-
weight form and the reduction of adiponectin in individuals
with CAD is attributed by the reduction of this form. The
molecular mechanism of signal transduction by adiponectin
might, therefore, be very complicated, although possible adipo-
nectin receptors have been reported from two institutes [46,47].
The search for enhancers of endogenous adiponectin syn-
thesis might be the most practical way for therapeutic appli-
cation related to adiponectin. Thiazolidinedione derivatives
have been shown to potently increase adiponectin synthesis.
Troglitazone treatment raised plasma concentrations of
adiponectin threefold in people with visceral obesity. Thiazo-
lidinedione might have unexpected functions as PPAR-c
agonists, however, and the search for derivatives that can
speciﬁcally enhance adiponectin production might be extre-
mely important. We have identiﬁed the peroxisome prolifer-ative activated receptor responsive element in the promoter
of the adiponectin gene and also identiﬁed a role for liver
receptor homologue as a cofactor [48]. In the near future,
active derivatives for speciﬁc enhancer of adiponectin syn-
thesis could be developed.
From these studies of adiponectin functions, we propose the
physiologic signiﬁcance of adiponectin with respect to cardio-
vascular disease prevention. Hypoadiponectinemia induced by
visceral fat accumulation becomes a strong risk factor not only
for diabetes mellitus, hypertension, but also atherosclerosis
and cardiac events. The suspected protective eﬀect of adipo-
nectin on injured vascular walls might lead to a role in emerg-
ing therapy for atherosclerosis.
In conclusion, adipocytes secrete various adipocytokines to
control the functions of other organs and cells. Production
and secretion of adipocytokines are considered to be dynami-
cally regulated mainly by the nutritional condition. Lifestyle
factors, such as overeating and physical inactivity, induce vis-
ceral fat accumulation, which results in the dysfunction of adi-
pocytes. Oversecretion of oﬀensive adipocytokines, such as
PAI-1, tumor necrosis factor-a or visfatin, and hyposecretion
of defensive adipocytokines, such as adiponectin, might be ma-
jor mechanisms of lifestyle-related diseases, including diabetes
mellitus, hyperlipidemia, hypertension and atherosclerosis,
comprising the so-called metabolic syndrome. The reduction
of visceral fat might be, therefore, an essential preventive mea-
sure for metabolic syndrome and its consequence, cardiovascu-
lar disease. The regulation of key adipocytokines such as
adiponectin might be considered as an eﬃcient therapeutic
procedure, but needs to be studied carefully.References
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